Gemmer Asset Management LLC Sells 123 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Gemmer Asset Management LLC trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.3% during the first quarter, Holdings Channel.com reports. The institutional investor owned 3,627 shares of the biopharmaceutical company’s stock after selling 123 shares during the quarter. Gemmer Asset Management LLC’s holdings in Gilead Sciences were worth $406,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of GILD. Brighton Jones LLC boosted its holdings in shares of Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after buying an additional 2,450 shares in the last quarter. Bleakley Financial Group LLC boosted its holdings in shares of Gilead Sciences by 10.5% during the 4th quarter. Bleakley Financial Group LLC now owns 25,484 shares of the biopharmaceutical company’s stock worth $2,354,000 after buying an additional 2,414 shares in the last quarter. YANKCOM Partnership bought a new position in shares of Gilead Sciences during the 4th quarter worth approximately $28,000. Adero Partners LLC bought a new position in shares of Gilead Sciences during the 4th quarter worth approximately $230,000. Finally, Beacon Financial Advisory LLC bought a new position in shares of Gilead Sciences during the 4th quarter worth approximately $206,000. 83.67% of the stock is currently owned by institutional investors.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 17,929 shares of the firm’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the completion of the sale, the chief financial officer now directly owns 169,061 shares of the company’s stock, valued at $19,977,938.37. This trade represents a 9.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the sale, the insider now directly owns 121,152 shares of the company’s stock, valued at approximately $13,026,263.04. This represents a 18.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 60,929 shares of company stock valued at $6,748,980. 0.27% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities analysts have issued reports on GILD shares. Wells Fargo & Company increased their price target on Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. Cantor Fitzgerald started coverage on Gilead Sciences in a report on Tuesday, April 22nd. They issued an “overweight” rating and a $125.00 target price on the stock. JPMorgan Chase & Co. increased their target price on Gilead Sciences from $120.00 to $130.00 and gave the stock an “overweight” rating in a report on Thursday, March 27th. Royal Bank of Canada increased their target price on Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a report on Wednesday, February 12th. Finally, BMO Capital Markets increased their target price on Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a report on Wednesday, February 12th. Nine analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $110.55.

Gilead Sciences Trading Up 1.8%

NASDAQ GILD opened at $112.46 on Friday. The firm has a market capitalization of $139.89 billion, a P/E ratio of 303.95, a PEG ratio of 0.71 and a beta of 0.26. The business has a fifty day simple moving average of $105.39 and a 200 day simple moving average of $101.47. Gilead Sciences, Inc. has a 12 month low of $62.69 and a 12 month high of $119.96. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.04. The business had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Gilead Sciences’s quarterly revenue was down .3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.32) EPS. On average, analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.81%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences’s payout ratio is currently 66.53%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.